1,7-dipiperidino-heptan-4-one | 500341-62-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1,7-dipiperidino-heptan-4-one
• 英文别名: 1,7-Dipiperidino-heptan-4-on；1,7-Di(piperidin-1-yl)heptan-4-one
• CAS: 500341-62-8
• 化学式: C₁₇H₃₂N₂O
• 分子量: 280.454
• InChiKey: UYCYOYFXVACSII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,7-dipiperidino-heptan-4-one 、 S-(4-叔-丁基苯甲基)[2-(1-甲基丁基)吡啶-3-基]硫代氨基甲酸酯 生成 1,7-dipiperidino-heptan-4-one semicarbazone
  参考文献：
  名称：

  The Acetoacetic Ester Condensation. VIII. The Condensation of ι-Piperidino Esters

  摘要：

  DOI：

  10.1021/ja01323a050
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 作用下， 生成 1,7-dipiperidino-heptan-4-one
  参考文献：
  名称：

  Petit, Bulletin de la Classe des Sciences, Academie Royale de Belgique, 1926, vol. <5> 12, p. 782

  摘要：

  DOI：

文献信息

• The Structure of C₇H₁₂O₂ from the Hydrogenation of Furylacrolein
  作者：Mark Farlow、Harold E. Burdick、Homer Adkins

  DOI：10.1021/ja01326a505

  日期：1934.11
• US4755522A
  申请人：——

  公开号：US4755522A

  公开（公告）日：1988-07-05
• [EN] NERVE DAMAGE<br/>[FR] ATTEINTE D'UN NERF
  申请人：ROELANTS IVO

  公开号：WO2005107744A1

  公开（公告）日：2005-11-17

  Present invention is directed to a novel medicament for medical treatment of nerve compression or nerve entrapment, such as carpal tunnel syndrome (CTS) or ulnar tunnel syndrome (UTS). More particularly it involves the use of aminoketones derivatives of phloroglucinol, to prevent, retard and ameliorate a nerve compression, a nerve entrapment or traumatic or physical nerve injury and the associated syndromes or axonal degeneration. Such aminoketone derivatives are preferably 2’,4’,6’-triemthoxy-4 (1-pyrrolidinyl) butyrophenone or pharmacologically acceptable salts and/or functional derivatives thereof. The medicament to prevent, retard and ameliorate a nerve compression, nerve entrapment or physical nerve injury syndromes can furthermore comprise magnesium (Mg), its pharmacologically acceptable salt or its derivatives, such as magnesium oxide, magnesium aspartate, magnesium sulphate, magnesium citrate chelated magnesium, magnesium EAP in an amount sufficient to treat, to prevent, to retard, to ameliorate of to cure physical or traumatic nerve injury, nerve compression or nerve entrapment and the associated syndromes or axonal degeneration.
• [EN] TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS<br/>[FR] TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE
  申请人：UNIV LEUVEN KATH

  公开号：WO2008034202A2

  公开（公告）日：2008-03-27

  [EN] Present invention is directed to a novel medicament for medical treatment of motor neuron disease (NMD) such as amyotrophic lateral sclerosis. More particularly the present invention involves the use of ivermectin and analogues, to prevent, retard and ameliorate a motor neuron disease (MND) such as amyotrophic lateral sclerosis (ALS) and the associated motor neuron degeneration.
  [FR] La présente invention concerne un nouveau médicament pour le traitement médical d'une maladie du neurone moteur (MND) telle que la sclérose latérale amyotrophique. Plus particulièrement, la présente invention concerne l'utilisation de l'ivermectine et d'analogues, pour prévenir, retarder et améliorer une maladie du neurone moteur (MND) telle que la sclérose latérale amyotrophique (ALS) et la dégénérescence associée des neurones moteurs.